Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Profit After Tax (2017 - 2026)

Denali Therapeutics has reported Profit After Tax over the past 9 years, most recently at -$128.5 million for Q4 2025.

  • Quarterly Profit After Tax fell 12.02% to -$128.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$512.5 million through Dec 2025, down 21.23% year-over-year, with the annual reading at -$512.5 million for FY2025, 21.23% down from the prior year.
  • Profit After Tax was -$128.5 million for Q4 2025 at Denali Therapeutics, down from -$126.9 million in the prior quarter.
  • Over five years, Profit After Tax peaked at $183.4 million in Q2 2023 and troughed at -$133.0 million in Q1 2025.
  • The 5-year median for Profit After Tax is -$100.6 million (2023), against an average of -$84.9 million.
  • Year-over-year, Profit After Tax skyrocketed 411.91% in 2023 and then tumbled 154.0% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$75.3 million in 2021, then plummeted by 31.11% to -$98.7 million in 2022, then fell by 21.07% to -$119.5 million in 2023, then grew by 3.95% to -$114.8 million in 2024, then decreased by 12.02% to -$128.5 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Profit After Tax are -$128.5 million (Q4 2025), -$126.9 million (Q3 2025), and -$124.1 million (Q2 2025).